Back to search
FDAFDA · Food and drugs·Recall number D-1343-2022

Rifampin Capsules, USP, 150 mg, 30 count HDPE bottles, Rx Only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD, 21202 NDC: 68180-658-06

Published August 24, 2022 · Recall initiated: July 28, 2022

Summary

FDA records drug Class II recall D-1343-2022, published August 24, 2022 and initiated July 28, 2022. Recalling firm: Lupin Pharmaceuticals Inc.; Status: Terminated; Reported quantity: 7,872/30 count bottles; Lot: Lot #A200170, exp. date December 2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations:OOS result was observed in 1-Methyl-4-Nitroso Piperazine (MNP) impurity.

What to do

Voluntary: Firm initiated · Letter

Get an email if RIFAMPIN has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
RIFAMPIN
Manufacturer
Lupin Pharmaceuticals Inc.
Distributor
Product was distributed nationwide.
Lot
Lot #A200170, exp. date December 2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Rifampin Capsules, USP, 150 mg, 30 count HDPE bottles, Rx Only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD, 21202 NDC: 68180-658-06 recalled?

Yes. FDA published recall D-1343-2022 on August 24, 2022. Reported hazard: CGMP Deviations:OOS result was observed in 1-Methyl-4-Nitroso Piperazine (MNP) impurity.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: RIFAMPIN.